Email this article SPECIFIC CHARACTERISTICS OF BRAIN METASTASIZING IN PATIENTS WITH LUMINAL SUBTYPE OF BREAST CANCER
- Authors: Balkanov A.S.1,2, Petrushkina N.N.1,2
-
Affiliations:
- Moscow Regional Research and Clinical Institute (MONIKI)
- 61/2 Shchepkina ul., Moscow, 129110, Russian Federation
- Issue: Vol 44, No 5 (2016)
- Pages: 635-639
- Section: ARTICLES
- URL: https://almclinmed.ru/jour/article/view/454
- DOI: https://doi.org/10.18786/2072-0505-2016-44-5-635-639
- ID: 454
Cite item
Full Text
Abstract
Background: More than half of female patients with breast cancer are diagnosed with a luminal subtype of the disease; however, specific characteristics of its metastases to the brain have been not well studied, unlike those of HER2 positive and triple negative subtypes. Aim: A comparative analysis of characteristics of metastatic brain lesions in patients with luminal breast cancer. Materials and methods: The time from surgery for breast cancer to the first recurrence and to metastatic brain lesions (assessed by contrast-enhanced MRI imaging) was measured in 41 patients with luminal subtype of breast cancer (median age, 49.5±9.6 years), depending on a diameter of the primary tumor and numbers of involved axillary lymph nodes. Results: The time interval to occurrence of brain metastases in luminal subtype of breast cancer is not associated with the size of the tumor. If≥4 axillary lymph nodes are involved (N2–3), brain metastases are identified much earlier (p<0.05) than in patients with N0–1 (34.5±23.9 months and 62.7±50 months, respectively). Neither the size nor the involvement of axillary lymph nodes has any impact on the rates of metastatic lesion to the brain during the first recurrence. Conclusion: Brain metastases occur at a much shorter time in those patients of luminal subtype of breast cancer who have metastases in≥4 axillary lymph nodes. Brain metastases develop in 50% of patients with the first recurrence of the luminal subtype of breast cancer.
About the authors
A. S. Balkanov
Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation
Author for correspondence.
Email: andreybalkanov@yandex.ru
MD, PhD, Head of Department of Radiology Россия
N. N. Petrushkina
Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation
Email: andreybalkanov@yandex.ru
MD, Specialist in Radiation Therapy, Department of Radiology Россия
References
- Гуров АН, Балканов АС, Катунцева НА, Огнева ЕЮ. Анализ онкозаболеваемости и смертности населения Московской области за 2014 год. Альманах клинической медицины. 2015;41:6–11. doi: 10.18786/2072-0505-2015-41-6-11.
- Gaudet MM, Press MF, Haile RW, Lynch CF, Glaser SL, Schildkraut J, Gammon MD, Douglas Thompson W, Bernstein JL. Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. Breast Cancer Res Treat. 2011;130(2): 587–97. doi: 10.1007/s10549-011-1616-x.
- Saha A, Ghosh SK, Roy C, Choudhury KB, Chakrabarty B, Sarkar R. Demographic and clinical profile of patients with brain metastases: A retrospective study. Asian J Neurosurg. 2013;8(3): 157–61. doi: 10.4103/1793-5482.121688.
- Barnholtz-Sloan JS, Sloan AE, Davis FG, Vi-gneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22(14): 2865–72. doi: 10.1200/ JCO.2004.12.149.
- Demircioglu F, Demirci U, Akmansu M. Lymph node ratio assessment of brain metastasis in early breast cancer cases. Asian Pac J Cancer Prev. 2013;14(3): 1665–7.
- Dawood S, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM. Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. Cancer. 2012;118(19): 4652–9. doi: 10.1002/cncr.27434.
- Niikura N, Saji S, Tokuda Y, Iwata H. Brain metastases in breast cancer. Jpn J Clin On-col. 2014;44(12): 1133–40. doi: 10.1093/jjco/ hyu156.
- Neman J, Termini J, Wilczynski S, Vaidehi N, Choy C, Kowolik CM, Li H, Hambrecht AC, Roberts E, Jandial R. Human breast cancer metastases to the brain display GABAergic properties in the neural niche. Proc Natl Acad Sci U S A. 2014;111(3): 984–9. doi: 10.1073/ pnas.1322098111.
- Duchnowska R, Jassem J, Goswami CP, Dun-dar M, Gökmen-Polar Y, Li L, Woditschka S, Biernat W, Sosińska-Mielcarek K, Czartoryska-Arłukowicz B, Radecka B, Tomasevic Z, Stępniak P, Wojdan K, Sledge GW Jr, Steeg PS, Badve S. Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients. J Neurooncol. 2015;122(1): 205–16. doi: 10.1007/s11060-014-1704-y.
- Zhang T, Li Q, Xu B, Zhang P, Yuan P, Ma F, Wang J, Fan Y. Breast cancer brain metastases: clinical and prognostic characteristics of different biological subtypes. Zhonghua Zhong Liu Za Zhi. 2014;36(9): 697–702.
- Berghoff AS, Bago-Horvath Z, Ilhan-Mutlu A, Magerle M, Dieckmann K, Marosi C, Birner P, Widhalm G, Steger GG, Zielinski CC, Bartsch R, Preusser M. Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors. Br J Cancer. 2012;107(9): 1454–8. doi: 10.1038/ bjc.2012.440.
Supplementary files
